+49 711 500 989 80
deen

CAR T drives acute myeloid leukemia into submission in pre-clinical studies



CAR T drives acute myeloid leukemia into submission in pre-clinical studies

Investigators have devised a novel method for improving CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumor-killing effect of a CAR T directed against acute myeloid leukemia.

Materials provided by Massachusetts General Hospital. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

27th September 2022

Rhombic lip implicated in origins of high-risk medulloblastoma

Read more
27th September 2022

How prostate cancer may begin

Read more
27th September 2022

Diets rich in refined fiber may increase liver cancer risk in some individuals

Read more